Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review

LC Price, SJ Wort, SJ Finney, PS Marino, SJ Brett - Critical Care, 2010 - Springer
Introduction Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting
right ventricular (RV) failure occur in many critical illnesses and may be associated with a …

Perioperative risk and management in patients with pulmonary hypertension

OA Minai, JP Yared, R Kaw, K Subramaniam, NS Hill - Chest, 2013 - Elsevier
Pulmonary hypertension (PH) is a known risk factor for perioperative complications. Unlike
in the case of cardiac surgery, PH is currently not listed as an independent risk factor for …

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

MR Costanzo, A Dipchand, R Starling… - The Journal of heart and …, 2010 - Elsevier
CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management

J Strumpher, E Jacobsohn - Journal of cardiothoracic and vascular …, 2011 - jcvaonline.com
From the Department of Anesthesia and Perioperative Medicine, University of Manitoba,
Winnipeg, Manitoba, Canada. Address reprint requests to Johann Strumpher, MBChB …

[HTML][HTML] Phosphodiesterase type 5 and cancers: Progress and challenges

I Barone, C Giordano, D Bonofiglio, S Andò… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Cancers are an extraordinarily heterogeneous collection of diseases with distinct genetic
profiles and biological features that directly influence response patterns to various treatment …

Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure

S Korkmaz‐Icöz, T Radovits… - British journal of …, 2018 - Wiley Online Library
Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into
5′‐GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP …

Current therapeutics and practical management strategies for pulmonary arterial hypertension

R Agarwal, M Gomberg-Maitland - American heart journal, 2011 - Elsevier
Pulmonary arterial hypertension (PAH) develops from an abnormal interaction between the
endothelium and smooth muscle cells in the pulmonary vasculature and is characterized by …

Implications of acute kidney injury after heart transplantation: what a surgeon should know

LS De Santo, G Romano, C Amarelli… - European journal of …, 2011 - academic.oup.com
Objective: Data regarding risks and consequences of acute kidney injury (AKI) after cardiac
transplantation are dismissingly few and unclear. This study defined the incidence, risk …

Prevention of Right Heart Failure After Left Ventricular Assist Device Implantation by P hosphodiesterase 5 Inhibitor

R Hamdan, H Mansour, P Nassar, M Saab - Artificial organs, 2014 - Wiley Online Library
Right ventricular (RV) function immediately after left ventricular assist device (LVAD)
implantation is a crucial prognostic factor. RV failure is linked to increased mortality and …

The management of acute pulmonary arterial hypertension

G Hui‐li - Cardiovascular therapeutics, 2011 - Wiley Online Library
Acute pulmonary arterial hypertension (PAH), which may complicate the course of many
complex disorders, is always underdiagnosed and its treatment frequently begins only after …